166 related articles for article (PubMed ID: 38254674)
41. Schisandrin B Ameliorates ICV-Infused Amyloid β Induced Oxidative Stress and Neuronal Dysfunction through Inhibiting RAGE/NF-κB/MAPK and Up-Regulating HSP/Beclin Expression.
Giridharan VV; Thandavarayan RA; Arumugam S; Mizuno M; Nawa H; Suzuki K; Ko KM; Krishnamurthy P; Watanabe K; Konishi T
PLoS One; 2015; 10(11):e0142483. PubMed ID: 26556721
[TBL] [Abstract][Full Text] [Related]
42. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
43. Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin.
Wang S; Wang A; Shao M; Lin L; Li P; Wang Y
Sci Rep; 2017 Aug; 7(1):8419. PubMed ID: 28827665
[TBL] [Abstract][Full Text] [Related]
44. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
45. Zerumbone suppresses IL-1β-induced cell migration and invasion by inhibiting IL-8 and MMP-3 expression in human triple-negative breast cancer cells.
Han J; Bae SY; Oh SJ; Lee J; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Nam SJ; Kim S; Lee JE
Phytother Res; 2014 Nov; 28(11):1654-60. PubMed ID: 24890258
[TBL] [Abstract][Full Text] [Related]
46. Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo.
He L; Chen H; Qi Q; Wu N; Wang Y; Chen M; Feng Q; Dong B; Jin R; Jiang L
Eur J Pharmacol; 2022 Apr; 920():174823. PubMed ID: 35157912
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of autophagy enhances the anticancer effect of Schisandrin B on head and neck squamous cell carcinoma.
Li M; Tang Q; Li S; Yang X; Zhang Y; Tang X; Huang P; Yin D
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23585. PubMed ID: 37986106
[TBL] [Abstract][Full Text] [Related]
49. Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathway.
Jiang Y; Zhang Q; Bao J; Du C; Wang J; Tong Q; Liu C
Biomed Pharmacother; 2015 Aug; 74():77-82. PubMed ID: 26349966
[TBL] [Abstract][Full Text] [Related]
50. Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.
Ma R; Zhan Y; Zhang Y; Wu L; Wang X; Guo M
Drug Dev Res; 2022 May; 83(3):735-744. PubMed ID: 34927282
[TBL] [Abstract][Full Text] [Related]
51. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
52. Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy.
Stămat LB; Dinescu S; Costache M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834660
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
[TBL] [Abstract][Full Text] [Related]
54. miR-1290 modulates the radioresistance of triple-negative breast cancer by targeting NLRP3-mediated pyroptosis.
Li Y; Li X
Clin Transl Oncol; 2022 Sep; 24(9):1764-1775. PubMed ID: 35471684
[TBL] [Abstract][Full Text] [Related]
55. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
56. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs).
Lappano R; Talia M; Cirillo F; Rigiracciolo DC; Scordamaglia D; Guzzi R; Miglietta AM; De Francesco EM; Belfiore A; Sims AH; Maggiolini M
J Exp Clin Cancer Res; 2020 Aug; 39(1):153. PubMed ID: 32778144
[TBL] [Abstract][Full Text] [Related]
57. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
58. Schisandrin A protects against lipopolysaccharide-induced mastitis through activating Nrf2 signaling pathway and inducing autophagy.
Xu D; Liu J; Ma H; Guo W; Wang J; Kan X; Li Y; Gong Q; Cao Y; Cheng J; Fu S
Int Immunopharmacol; 2020 Jan; 78():105983. PubMed ID: 31767544
[TBL] [Abstract][Full Text] [Related]
59. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
60.
Wang KN; Hu Y; Han LL; Zhao SS; Song C; Sun SW; Lv HY; Jiang NN; Xv LZ; Zhao ZW; Li M
Front Oncol; 2022; 12():882784. PubMed ID: 36033499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
